<p>Bright Minds Biosciences（纳斯达克代码：DRUG - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 的投资分析师从 “持有” 评级下调至 “卖出” 评级。</p>
<ul>
<li>生物科技处于边缘：两只潜力巨大的股票</li>
</ul>
<p>其他几位股票研究分析师也对 DRUG 发布了报告。Cantor Fitzgerald 在 12 月 1 日的研究报告中重申了对 Bright Minds Biosciences 股票的 “增持” 评级。BTIG Research 将 Bright Minds Biosciences 的目标价格从 72.00 美元提高至 147.00 美元，并在周二的报告中给予该公司 “买入” 评级。Chardan Capital 在 1 月 2 日的研究报告中重申了 “买入” 评级，并设定了 80.00 美元的目标价格。HC Wainwright 在 12 月 30 日的研究报告中重申了 “买入” 评级，并设定了 115.00 美元的目标价格。最后，Robert W. Baird 在周三设定了 Bright Minds Biosciences 的目标价格为 142.00 美元。七位投资分析师对该股票给予了 “买入” 评级，一位分析师给予了 “持有” 评级。根据 MarketBeat.com 的数据，Bright Minds Biosciences 目前的共识评级为 “适度买入”，平均目标价格为 115.40 美元。</p>
<p><strong>查看我们对 Bright Minds Biosciences 的最新分析</strong></p>
<h2>Bright Minds Biosciences 股价下跌 3.6%</h2>
<ul>
<li>Bright Minds Biosciences 股票飙升近 1500%</li>
</ul>
<p>DRUG 在周五开盘价为 86.75 美元。该公司的市值为 6.7578 亿美元，市盈率为-71.11，贝塔值为-6.15。Bright Minds Biosciences 的 12 个月低点为 23.17 美元，12 个月高点为 123.75 美元。该股票的 50 日移动平均线为 73.17 美元，200 日移动平均线为 53.59 美元。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金最近对该股票的持仓进行了调整。高盛集团在第一季度购买了 Bright Minds Biosciences 的新股份，价值约为 802,000 美元。Sio Capital Management LLC 在第二季度将其在 Bright Minds Biosciences 的持股增加了 0.9%。Sio Capital Management LLC 目前拥有 512,338 股该公司的股票，价值为 13,377,000 美元，在上个季度又增持了 4,776 股。新泽西州警察和消防员退休系统在第二季度购买了 Bright Minds Biosciences 的新股份，价值约为 28,000 美元。AdvisorShares Investments LLC 在第二季度将其在 Bright Minds Biosciences 的持仓增加了 28.4%。AdvisorShares Investments LLC 目前拥有 14,481 股该公司的股票，价值为 378,000 美元，在此期间又增持了 3,200 股。最后，摩根大通在第三季度将其在 Bright Minds Biosciences 的持股增加了 142.3%。摩根大通目前拥有 5,265 股该公司的股票，价值为 319,000 美元，在上个季度又增持了 3,092 股。当前 40.52% 的股票由机构投资者持有。</p>
<h2>Bright Minds Biosciences 公司简介</h2>
<p>(获取免费报告)</p>
<p>Bright Minds Biosciences Inc 在纳斯达克以 DRUG 为交易代码，是一家临床阶段的生物技术公司，专注于开发用于心理健康和神经退行性疾病的新型小分子治疗药物。该公司的研究利用专有化学平台创造源自迷幻药结构的调节血清素和神经保护化合物。Bright Minds 旨在通过口服治疗解决重度抑郁症、创伤后应激障碍和阿尔茨海默病等未满足的需求。</p>
<p>该公司的主要候选药物 BMB-101 是一种口服 5-HT2A 受体调节化合物，正在临床开发中，针对情绪和焦虑障碍。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Bright Minds Biosciences 更好</li>
<li>华尔街选股者评选 2026 年第一只股票</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护您的财富</li>
<li>市场恐慌：特朗普刚刚对您的股票投下了一颗炸弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Bright Minds Biosciences 吗？</h2>
<p>在您考虑 Bright Minds Biosciences 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Bright Minds Biosciences 并不在名单上。</p>
<p>虽然 Bright Minds Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

DRUG

<p>华尔街禅将 Bright Minds Biosciences（纳斯达克代码：DRUG）的评级从 “持有” 下调至 “卖出”。尽管如此，几位分析师仍然保持乐观的展望，Cantor Fitzgerald 重申了 “增持” 评级，而 BTIG Research 则将目标价格上调至 147 美元。该股票的共识评级为 “适度买入”，平均目标价格为 115.40 美元。Bright Minds 专注于开发针对心理健康和神经退行性疾病的治疗药物，其主要候选药物正在针对情绪和焦虑障碍进行临床开发</p>

<p>Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report issued on Saturday.</p>
<div class="lb-trans"><p>Bright Minds Biosciences（纳斯达克代码：DRUG - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 的投资分析师从 “持有” 评级下调至 “卖出” 评级。</p>
</div><ul>
<li>Biotechs on the Brink: 2 Stocks With Huge Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技处于边缘：两只潜力巨大的股票</li>
</ul>
</div><p>Several other equities research analysts have also issued reports on DRUG. Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating on shares of Bright Minds Biosciences in a research note on Monday, December 1st. BTIG Research increased their price target on Bright Minds Biosciences from $72.00 to $147.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday. Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $80.00 price objective on shares of Bright Minds Biosciences in a research note on Friday, January 2nd. HC Wainwright reiterated a &#34;buy&#34; rating and set a $115.00 price objective on shares of Bright Minds Biosciences in a research report on Tuesday, December 30th. Finally, Robert W. Baird set a $142.00 target price on shares of Bright Minds Biosciences in a report on Wednesday. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Bright Minds Biosciences currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $115.40.</p>
<div class="lb-trans"><p>其他几位股票研究分析师也对 DRUG 发布了报告。Cantor Fitzgerald 在 12 月 1 日的研究报告中重申了对 Bright Minds Biosciences 股票的 “增持” 评级。BTIG Research 将 Bright Minds Biosciences 的目标价格从 72.00 美元提高至 147.00 美元，并在周二的报告中给予该公司 “买入” 评级。Chardan Capital 在 1 月 2 日的研究报告中重申了 “买入” 评级，并设定了 80.00 美元的目标价格。HC Wainwright 在 12 月 30 日的研究报告中重申了 “买入” 评级，并设定了 115.00 美元的目标价格。最后，Robert W. Baird 在周三设定了 Bright Minds Biosciences 的目标价格为 142.00 美元。七位投资分析师对该股票给予了 “买入” 评级，一位分析师给予了 “持有” 评级。根据 MarketBeat.com 的数据，Bright Minds Biosciences 目前的共识评级为 “适度买入”，平均目标价格为 115.40 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Bright Minds Biosciences</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Bright Minds Biosciences 的最新分析</strong></p>
</div><h2>Bright Minds Biosciences Trading Down 3.6%</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 股价下跌 3.6%</h2>
</div><ul>
<li>Bright Minds Biosciences Stock Surges Almost 1,500%</li>
</ul>
<div class="lb-trans"><ul>
<li>Bright Minds Biosciences 股票飙升近 1500%</li>
</ul>
</div><p>DRUG opened at $86.75 on Friday. The firm has a market cap of $675.78 million, a P/E ratio of -71.11 and a beta of -6.15. Bright Minds Biosciences has a 12 month low of $23.17 and a 12 month high of $123.75. The stock has a 50-day moving average of $73.17 and a 200 day moving average of $53.59.</p>
<div class="lb-trans"><p>DRUG 在周五开盘价为 86.75 美元。该公司的市值为 6.7578 亿美元，市盈率为-71.11，贝塔值为-6.15。Bright Minds Biosciences 的 12 个月低点为 23.17 美元，12 个月高点为 123.75 美元。该股票的 50 日移动平均线为 73.17 美元，200 日移动平均线为 53.59 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. bought a new stake in Bright Minds Biosciences during the 1st quarter valued at about $802,000. Sio Capital Management LLC grew its stake in Bright Minds Biosciences by 0.9% in the 2nd quarter. Sio Capital Management LLC now owns 512,338 shares of the company's stock worth $13,377,000 after acquiring an additional 4,776 shares in the last quarter. Police &amp; Firemen s Retirement System of New Jersey purchased a new position in shares of Bright Minds Biosciences during the second quarter worth approximately $28,000. AdvisorShares Investments LLC increased its position in shares of Bright Minds Biosciences by 28.4% during the second quarter. AdvisorShares Investments LLC now owns 14,481 shares of the company's stock worth $378,000 after acquiring an additional 3,200 shares during the period. Finally, JPMorgan Chase &amp; Co. raised its stake in shares of Bright Minds Biosciences by 142.3% during the third quarter. JPMorgan Chase &amp; Co. now owns 5,265 shares of the company's stock valued at $319,000 after acquiring an additional 3,092 shares in the last quarter. 40.52% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金最近对该股票的持仓进行了调整。高盛集团在第一季度购买了 Bright Minds Biosciences 的新股份，价值约为 802,000 美元。Sio Capital Management LLC 在第二季度将其在 Bright Minds Biosciences 的持股增加了 0.9%。Sio Capital Management LLC 目前拥有 512,338 股该公司的股票，价值为 13,377,000 美元，在上个季度又增持了 4,776 股。新泽西州警察和消防员退休系统在第二季度购买了 Bright Minds Biosciences 的新股份，价值约为 28,000 美元。AdvisorShares Investments LLC 在第二季度将其在 Bright Minds Biosciences 的持仓增加了 28.4%。AdvisorShares Investments LLC 目前拥有 14,481 股该公司的股票，价值为 378,000 美元，在此期间又增持了 3,200 股。最后，摩根大通在第三季度将其在 Bright Minds Biosciences 的持股增加了 142.3%。摩根大通目前拥有 5,265 股该公司的股票，价值为 319,000 美元，在上个季度又增持了 3,092 股。当前 40.52% 的股票由机构投资者持有。</p>
</div><h2>Bright Minds Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.</p>
<div class="lb-trans"><p>Bright Minds Biosciences Inc 在纳斯达克以 DRUG 为交易代码，是一家临床阶段的生物技术公司，专注于开发用于心理健康和神经退行性疾病的新型小分子治疗药物。该公司的研究利用专有化学平台创造源自迷幻药结构的调节血清素和神经保护化合物。Bright Minds 旨在通过口服治疗解决重度抑郁症、创伤后应激障碍和阿尔茨海默病等未满足的需求。</p>
</div><p>The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.</p>
<div class="lb-trans"><p>该公司的主要候选药物 BMB-101 是一种口服 5-HT2A 受体调节化合物，正在临床开发中，针对情绪和焦虑障碍。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Bright Minds Biosciences</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Do not delete, read immediately</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Bright Minds Biosciences 更好</li>
<li>华尔街选股者评选 2026 年第一只股票</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护您的财富</li>
<li>市场恐慌：特朗普刚刚对您的股票投下了一颗炸弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=DRUG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bright Minds Biosciences Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Bright Minds Biosciences 吗？</h2>
</div><p>Before you consider Bright Minds Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Bright Minds Biosciences 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bright Minds Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Bright Minds Biosciences 并不在名单上。</p>
</div><p>While Bright Minds Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bright Minds Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bright Minds Biosciences（纳斯达克股票代码：DRUG）在 Wall Street Zen 被下调至 “卖出” 评级